What is the 13F Pro Quality Score for TOI?

13F Pro ranks Oncology Institute, Inc. (TOI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TOI's current score at https://13fpro.ai/research/TOI (free sign-up required for the full ranking).

Where does 13F Pro source TOI data?

All Oncology Institute, Inc. fundamentals and ownership data come directly from SEC EDGAR. Oncology Institute, Inc. files with the SEC under CIK 1799191. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TOI in?

Oncology Institute, Inc. (TOI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TOI research updated on 13F Pro?

TOI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Oncology Institute, Inc.(TOI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1799191 TOI stock profile & AI dashboard →

13F Pro Quality Score

37.8/100

Rank #2,039 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

83.6/100

Profitability

26.9/100

Balance Sheet

6.5/100

Earnings Quality

30.0/100

Free Cash Flow

22.1/100

Institutional Flow

27.7/100

Revenue Scale

37.1/100

Dilution Risk

59.8/100

TOI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Oncology Institute, Inc. (TOI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TOI at 37.8/100 on a 32-signal composite quality model, placing it at rank #2,039 of 2,879 stocks — the bottom half of the AI-ranked universe. TOI scores in the top quartile across revenue growth (83.6). Areas of concern include balance sheet strength (6.5) and free cash flow (22.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Oncology Institute, Inc. reports quarterly revenue of $147.4M, net income of $-2.5M, an operating margin of -4.4%. Top institutional holders of TOI by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), based on the most recent SEC filings. TOI trades on the Nasdaq exchange and files with the SEC under CIK 1799191. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TOI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Oncology Institute, Inc. directly from SEC EDGAR. Oncology Institute, Inc.'s 13F Pro composite quality score has ranged between 32 and 38 since 2024, currently 37.8 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.

Revenue

Q1 2026

$147.4M

Net Income

Q1 2026

$-2.5M

Free Cash Flow

Q1 2026

$-3.3M

Operating Margin

Q1 2026

-4.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+55.0% YoY

$502.7MFY 2025

FY20 $187.5MFY21 $203.0MFY23 $324.2MFY25 $502.7M

Net Income

+27.0% YoY

$-60.6MFY 2025

FY20 $-14.3MFY21 $-10.9MFY23 $-83.1MFY25 $-60.6M

Operating Income

+53.1% YoY

$-36.1MFY 2025

FY20 $-683.9KFY21 $-45.9MFY23 $-77.0MFY25 $-36.1M

EPS (Diluted)

+41.3% YoY

$-0.54FY 2025

FY20 $-0.06FY21 $-0.16FY23 $-0.92FY25 $-0.54

Total Assets

-21.3% YoY

$164.7MFY 2025

FY20 $231.3MFY21 $203.4MFY23 $209.2MFY25 $164.7M

Total Debt

-10.9% YoY

$77.4MFY 2025

FY20 $17.3MFY21 $366.0KFY23 $86.8MFY25 $77.4M

Op. Cash Flow

+32.3% YoY

$-24.6MFY 2025

FY20 $-582.5KFY21 $-32.7MFY23 $-36.3MFY25 $-24.6M

Metric	FY 2025	FY 2023	FY 2021	FY 2020
Revenue	$502.7M +55.0%	$324.2M +59.7%	$203.0M +8.3%	$187.5M
Net Income	$-60.6M +27.0%	$-83.1M -660.2%	$-10.9M +23.7%	$-14.3M
Operating Income	$-36.1M +53.1%	$-77.0M -67.9%	$-45.9M -6605.7%	$-683.9K
EPS (Diluted)	$-0.54 +41.3%	$-0.92 -475.0%	$-0.16 -166.7%	$-0.06
Total Assets	$164.7M -21.3%	$209.2M +2.9%	$203.4M -12.1%	$231.3M
Total Debt	$77.4M -10.9%	$86.8M +23623.0%	$366.0K -97.9%	$17.3M
Operating Cash Flow	$-24.6M +32.3%	$-36.3M -11.1%	$-32.7M -5510.0%	$-582.5K

AI Insight: TOI Financial Trends

Revenue surged 48% from Q2 2024 to Q1 2026 and net losses narrowed sharply to -$2M, but equity turned deeply negative at -$16M.

• Revenue grew from $99M in Q2 2024 to $147M in Q1 2026, a 48% increase over eight quarters.

• Net loss narrowed dramatically from -$16M in Q3 2024 to -$2M in Q1 2026, the best result in the dataset.

• Operating loss improved from -$16M in Q2 2024 to -$7M in Q1 2026, though progress stalled over the last two quarters.

• Equity deteriorated from $29M in Q2 2024 to -$16M in Q1 2026, reflecting cumulative losses eroding the balance sheet.

⚠ Equity is -$16M and worsening; continued losses could deepen insolvency risk on the balance sheet.

⚠ Operating cash flow remains negative at -$2M in Q1 2026 despite revenue growth — conversion to positive FCF is unproven.

⚠ Total debt ticked up to $79M in Q1 2026 after declining from $93M — monitor whether debt reduction resumes.

AI Insight: TOI Ratio Trends

TOI's operating margin has nearly halved from -16.6% in Q2 2024 to -4.4% in Q1 2026, signaling meaningful but still-negative profitability progress.

• Operating margin improved steadily from -16.6% in Q2 2024 to -4.4% in Q1 2026, the best level in the dataset.

• Net profit margin narrowed sharply to -1.7% in Q1 2026 from -18.8% in Q1 2025, a dramatic year-over-year improvement.

• ROA recovered from -47.8% in Q1 2025 to -5.9% in Q1 2026, though remains deeply negative.

• ROIC remains deeply negative at -41.8% in Q1 2026, improving only modestly from -54.9% in Q2 2024.

⚠ D/E spiked to 25.95x in Q4 2024 before going unreported; leverage trajectory post-spike warrants close monitoring.

⚠ ROIC deteriorated to -67.9% in Q2 2025 mid-trend — confirms improvement is not yet linear or guaranteed.

⚠ ROE is unavailable across all periods, limiting full assessment of shareholder return dynamics.

Get alerted when TOI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Oncology Institute, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TOI

BlackRock, Inc.
$13.6M4,415,867 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.7M3,476,781 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$10.3M3,360,052 sh
Kanen Wealth Management LLC
$8.5M2,777,858 sh
JOSH ARNOLD INVESTMENT CONSULTANT, LLC
$7.6M2,464,359 sh
BALYASNY ASSET MANAGEMENT L.P.
$5.6M1,826,370 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.4M1,757,847 sh
WEXFORD CAPITAL LP
$5.3M1,711,323 sh
CITADEL ADVISORS LLC
$5.2M1,703,000 sh
CenterBook Partners LP
$4.8M1,568,423 sh

Fund	Value	Shares
BlackRock, Inc.	$13.6M	4,415,867
VANGUARD CAPITAL MANAGEMENT LLC	$10.7M	3,476,781
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$10.3M	3,360,052
Kanen Wealth Management LLC	$8.5M	2,777,858
JOSH ARNOLD INVESTMENT CONSULTANT, LLC	$7.6M	2,464,359
BALYASNY ASSET MANAGEMENT L.P.	$5.6M	1,826,370
GEODE CAPITAL MANAGEMENT, LLC	$5.4M	1,757,847
WEXFORD CAPITAL LP	$5.3M	1,711,323
CITADEL ADVISORS LLC	$5.2M	1,703,000
CenterBook Partners LP	$4.8M	1,568,423

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TOI on your watchlist

Track score changes the day Oncology Institute, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TOI a good stock to buy?

13F Pro's AI-powered analysis of Oncology Institute, Inc. (TOI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TOI are available on the TOI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TOI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TOI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Oncology Institute, Inc.'s investment landscape.